| Authors |
Lu L, Erhard P, Salomon RG, Weiss MF
|
| Submitted By |
Submitted Externally on 10/1/2015 |
| Status |
Published |
| Journal |
American journal of kidney diseases : the official journal of the National Kidney Foundation |
| Year |
2007 |
| Date Published |
8/1/2007 |
| Volume : Pages |
50 : 305 - 13 |
| PubMed Reference |
17660032 |
| Abstract |
Patients with end-stage renal disease have increased circulating concentrations
of oxidatively modified circulating proteins. Therefore, we examined the ability
of vitamin E alpha (alpha-tocopherol) to alter levels of these modified
proteins., Randomized clinical trial., 27 clinically stable patients treated by
means of hemodialysis in 4 freestanding outpatient dialysis units., Oral
administration of 800 IU of vitamin E alpha or placebo daily., Plasma levels of
alpha- and gamma-tocopherol and oxidative protein modifications reflecting 2
pathways for protein-oxidant damage. The advanced glycation end product
pentosidine reflects glycoxidation. The lipid peroxidation products
iso[4]-levuglandin E(2), (E)-4-hydroxy-2-nonenal, and (E)-4-oxo-2-nonenal are
formed through covalent adduction., Circulating levels of all oxidative protein
modifications were increased in patients with end-stage renal disease.
Supplementation with alpha-tocopherol caused alpha-tocopherol levels to rise
(13.2 +/- 3.7 to 27.3 +/- 14 mug/mL), but gamma-tocopherol levels to decrease
(4.1 +/- 1.6 to 3.5 +/- 1.1 mug/mL). Control values were unchanged. There was no
effect on oxidative protein modifications (placebo versus treatment; mean for
pentosidine, 15.6 +/- 11.4 (SD): 95% confidence interval (CI), 8.2 to 23.1
versus 21.3 +/- 9.0 pg/mg protein; 95% CI, 16.1 to 26.6; iso[4]-levuglandin
E(2), 8.31 +/- 2.55; 95% CI, 6.77 to 9.85 versus 8.46 +/- 2.37 nmol/mL; 95% CI,
7.09 to 9.84; (E)-4-hydroxy-2-nonenal, 0.51 +/- 0.11; 95% CI, 0.45 to 0.57
versus 0.51 +/- 0.08 nmol/mL; 95% CI, 0.46 to 0.56; (E)-4-oxo-2-nonenal, 189 +/-
44; 95% CI, 162 to 215 vs 227 +/- 72 pmol/mL; 95% CI, 183 to 271)., Sample size
was adequate to show changes in alpha- and gamma-tocopherol levels in response
to treatment. However, power was insufficient to show an effect on oxidative
protein modifications., Intervention of oral supplementation with
alpha-tocopherol did not result in changes in circulating oxidative protein
modifications. A larger study may be required to show an effect in this clinical
setting.
|
|
|